IP Library › Granted Patent US 11,141,312
Granted Patent B2
US 11,141,312 · App. 14/690,874 · Granted Oct 12, 2021

Lacrimal implant detection

Inventors: Eugene de Juan, Jr. (San Francisco, CA); Stephen Boyd (Murrieta, CA); Cary J. Reich (Los Gatos, CA); Christopher V. Cardenas (Redwood City, CA); Tommy Jewell (Albuquerque, NM); Lorrie Ma (San Jose, CA); Tuan Nguyen (San Jose, CA)
Assignee: Mati Therapeutics Inc.
A61F9/0017A61B5/06A61B5/411A61F9/00772A61L31/043A61L31/044A61L31/06A61L31/145A61L31/16G01R33/0213G01R33/072A61B5/0031A61B8/0833A61B2562/08A61F2250/0068A61F2250/0096A61L2300/404A61L2300/43
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,141,312
App. No.
14/690,874
Granted
Oct 12, 2021
Kind
B2
Abstract

This document discusses, among other things, an apparatus comprising a lacrimal implant insertable at least partially into a lacrimal punctum. The lacrimal implant comprises an implant core, and an implant body. The implant body includes a cavity sized and shaped to receive the implant core. At least one of the implant core and the implant cavity includes a detection device configured to allow automatic detection of the lacrimal implant with a separate detector device.

Claims (51)

1. A lacrimal implant for insertion into a lacrimal canaliculus of a patient comprising:

a therapeutic agent and a contrast agent admixed with biocompatible material comprising a hydrogel polymer wherein the contrast agent is configured to optically distinguish the lacrimal implant from a region of an eye and wherein a release rate of the therapeutic agent and contrast agent are different.

2. The lacrimal implant of claim 1 , wherein the contrast agent includes a material visible when illuminated with a 600-1300 nanometer light source.

3. The lacrimal implant of claim 1 , wherein the contrast agent comprises a color material, a pigment, a luminescent material, or a dye.

4. The lacrimal implant of claim 1 , wherein the therapeutic agent comprises travoprost, a non-steroidal anti-inflammatory agent (NSAID), anti-glaucoma drugs, prostaglandin analogues, a corticosteroid, an anti-inflammatory agent, an anti-allergy agent, antimicrobial agents, cycloplegic drugs, or mydriatic drugs.

5. The lacrimal implant of claim 1 , wherein the contrast agent comprises fluorescein.

6. The lacrimal implant of claim 1 , wherein the lacrimal implant is green.

7. The lacrimal implant of claim 1 , wherein the therapeutic agent is travoprost.

8. The lacrimal implant of claim 1 , wherein the therapeutic agent is dexamethasone.

9. The lacrimal implant of claim 1 , wherein the therapeutic agent is an antimicrobial agent.

10. The lacrimal implant of claim 1 , wherein the contrast agent comprises a material visible when illuminated with a visible light source.

11. The lacrimal implant of claim 1 , wherein the biocompatible material is biodegradable.

12. The lacrimal implant of claim 1 , wherein the biocompatible material comprises a biodegradable hydrogel polymer.

13. A lacrimal implant for insertion into a lacrimal canaliculus of a patient comprising:

a therapeutic agent and a contrast agent admixed with a biodegradable material comprising a hydrogel polymer wherein the contrast agent is configured to optically distinguish the lacrimal implant from a region of an eye and wherein a release rate of the therapeutic agent and contrast agent are different.

14. The lacrimal implant of claim 13 , wherein the contrast agent includes a material visible when illuminated with a 600-1300 nanometer light source.

15. The lacrimal implant of claim 13 , wherein the contrast agent comprises a color material, a pigment, a luminescent material, or a dye.

16. The lacrimal implant of claim 13 , wherein the therapeutic agent comprises travoprost, a non-steroidal anti-inflammatory agent (NSAID), anti-glaucoma drugs, prostaglandin analogues, a corticosteroid, an anti-inflammatory agent, an anti-allergy agent, antimicrobial agents, cycloplegic drugs, or mydriatic drugs.

17. The lacrimal implant of claim 13 , wherein the contrast agent comprises fluorescein.

18. The lacrimal implant of claim 13 , wherein the lacrimal implant is green.

19. The lacrimal implant of claim 13 , wherein the therapeutic agent is travoprost.

20. The lacrimal implant of claim 13 , wherein the therapeutic agent is dexamethasone.

21. The lacrimal implant of claim 13 , wherein the therapeutic agent is an antimicrobial agent.

22. The lacrimal implant of claim 13 , wherein the contrast agent comprises a material visible when illuminated with a visible light source.

23. The lacrimal implant of claim 13 , wherein the biodegradable material comprises a biodegradable hydrogel polymer.

24. A lacrimal implant for insertion into a lacrimal canaliculus of a patient comprising:

a therapeutic agent and a contrast agent admixed with a biodegradable hydrogel polymer wherein the contrast agent comprises a color material, a pigment, a luminescent material, or a dye, and wherein a release rate of the therapeutic agent and contrast agent are different.

25. The lacrimal implant of claim 24 , wherein the contrast agent is visible when illuminated with a 600-1300 nanometer light source.

26. The lacrimal implant of claim 24 , wherein the therapeutic agent comprises travoprost, a non-steroidal anti-inflammatory agent (NSAID), anti-glaucoma drugs, prostaglandin analogues, a corticosteroid, an anti-inflammatory agent, an anti-allergy agent, antimicrobial agents, cycloplegic drugs, or mydriatic drugs.

27. The lacrimal implant of claim 24 , wherein the contrast agent comprises fluorescein.

28. The lacrimal implant of claim 24 , wherein the lacrimal implant is green.

29. The lacrimal implant of claim 24 , wherein the therapeutic agent is travoprost.

30. The lacrimal implant of claim 24 , wherein the therapeutic agent is dexamethasone.

31. The lacrimal implant of claim 24 , wherein the therapeutic agent is an antimicrobial agent.

32. The lacrimal implant of claim 24 , wherein the contrast agent is visible when illuminated with a visible light source.

33. A lacrimal implant for insertion into a lacrimal canaliculus of a patient comprising:

a therapeutic agent, a detection agent and hydrogel polymers that form a hydrogel matrix with the therapeutic agent and detection agent dispersed through the hydrogel matrix, wherein the shape of the lacrimal implant consists of a constant diameter cylinder, and wherein a release rate of the therapeutic agent and detection agent are different.

34. The lacrimal implant of claim 33 , wherein the detection agent comprises a color material, a pigment, a luminescent material, or a dye.

35. The lacrimal implant of claim 33 , wherein the therapeutic agent comprises travoprost, a non-steroidal anti-inflammatory agent (NSAID), anti-glaucoma drugs, prostaglandin analogues, a corticosteroid, an anti-inflammatory agent, an anti-allergy agent, antimicrobial agents, cycloplegic drugs, or mydriatic drugs.

36. The lacrimal implant of claim 33 , wherein the detection agent comprises fluorescein.

37. The lacrimal implant of claim 33 , wherein the lacrimal implant is green.

38. The lacrimal implant of claim 33 , wherein the therapeutic agent is travoprost.

39. The lacrimal implant of claim 33 , wherein the therapeutic agent is dexamethasone.

40. The lacrimal implant of claim 33 , wherein the therapeutic agent is an antimicrobial agent.

41. The lacrimal implant of claim 34 , wherein the detection agent comprises a material visible when illuminated with a visible light source.

42. A lacrimal implant for insertion into a lacrimal canaliculus of a patient comprising:

a therapeutic agent, fluorescein and hydrogel polymers that form a hydrogel matrix with the therapeutic agent and fluorescein dispersed through the hydrogel matrix, wherein the shape of the lacrimal implant consists of a constant diameter cylinder, and wherein a release rate of the therapeutic agent and the fluorescein are different.

43. The lacrimal implant of claim 42 , wherein the therapeutic agent comprises travoprost, a non-steroidal anti-inflammatory agent (NSAID), anti-glaucoma drugs, prostaglandin analogues, a corticosteroid, an anti-inflammatory agent, an anti-allergy agent, antimicrobial agents, cycloplegic drugs, or mydriatic drugs.

44. The lacrimal implant of claim 42 , wherein the therapeutic agent is travoprost.

45. The lacrimal implant of claim 42 , wherein the therapeutic agent is dexamethasone.

46. The lacrimal implant of claim 42 , wherein the therapeutic agent is an antimicrobial agent.

Continuity (4)
Continuation 12231987 · Sep 5, 2008
Provisional Application 61050901 · May 6, 2008
Provisional Application 60970807 · Sep 7, 2007
Related Publication 20150374541A1 · Dec 31, 2015